Abstract
Ginkgo Bioworks has agreed to use its synthetic biology capabilities to improve the production of an unidentified biobased chemical from Sumitomo Chemical and make other Sumitomo products. An earlier agreement between Sumitomo and Zymergen, a Ginkgo competitor, yielded a biobased film for use in displays and touch screens. Both Sumitomo partners are riding high with investors at the moment. Zymergen made a successful initial public offering in May, while Ginkgo is in the process of going public by merging with a special purpose acquisition company, or SPAC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
